SCHEMBL4777062

SCHEMBL4777062

CSCCOCc1csc(NC(=O)O)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 5/20 0.43
LMNA P02545 7/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 3/20 0.43
HTT P42858 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 1/20 0.43
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
TSHR P16473 1/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.40
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4782084 0.84 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4959287 0.83 MAPK1 (0.56) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4779029 0.82 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4779874 0.81 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL1742457 0.79 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4726533 0.77 RAB9A (0.64) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4778961 0.76 ROCK1 (0.42) SMN1; SMN2MAPK1TSHR
SCHEMBL4779136 0.75 GRM5 (0.47) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4779877 0.73 KMT2A (0.48) SMN1; SMN2NPC1RAB9ALMNAKMT2A
SCHEMBL465934 0.72 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8716320-B2 Antibacteriall heterocyclic ureas REPLIDYNE, INC. (US) 2014-05-06 US disclosed
US-20080207703-A1 Antibacterial heterocyclic ureas REPLIDYNE, INC. (US) 2008-08-28 US disclosed
WO-2008011191-A1 ANTIBACTERIAL HETEROCYCLIC UREAS REPLIDYNE, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207703-A1 Antibacterial heterocyclic ureas UMPS, UROD, UGP2 SMN1; SMN2 4077/4885NPC1 2049/4885RAB9A 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.